Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prior-authorization programs for controlling drug spending.

× No keyword cloud information.

7 in total

Review 1. Impact of pharmaceutical prior authorisation policies : a systematic review of the literature.

Authors: Jaume Puig-Junoy; Iván Moreno-Torres
Journal: Pharmacoeconomics Date: 2007 Impact factor: 4.981

2. Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers.

Authors: Bruce A Feinberg; James Lang; James Grzegorczyk; Donna Stark; Thomas Rybarczyk; Thomas Leyden; Joseph Cooper; Thomas Ruane; Scott Milligan; Philip Stella; Jeffrey A Scott
Journal: J Oncol Pract Date: 2012-05 Impact factor: 3.840

3. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.

Authors: Michael R Law; Christine Y Lu; Stephen B Soumerai; Amy Johnson Graves; Robert F LeCates; Fang Zhang; Dennis Ross-Degnan; Alyce S Adams
Journal: Clin Ther Date: 2010-04 Impact factor: 3.393

Prior-authorization programs for controlling drug spending.

Review 1. Impact of pharmaceutical prior authorisation policies : a systematic review of the literature.

2. Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers.

3. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.

4. Impact of drug policy on regional trends in ezetimibe use.

5. Prior Authorization as a Potential Support of Patient-Centered Care.

6. Impact of Medicaid prior authorization requirement for COX-2 inhibitor drugs in Nebraska.

Review 7. Preferred drug lists: potential impact on healthcare economics.